Our results were consistent with previous reports in thyroid and ovarian cancers in which miR-218 overexpression via lipid-based transfection downregulates Runx2 and inhibits cell proliferation, migration, and invasion in vitro [10, 12]. This evidence concerns the gene RUNX2 and ovarian carcinoma.